Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

NCT02045797 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Bacterial

Interventions

DRUG: GSK2140944 Lyophile
DRUG: GSK2140944 Capsules

Sponsor

GlaxoSmithKline